Barbara Ruepp
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Rabaglio M, Thürlimann B, Colleoni M, Goldhirsch A, Gelber R, Coates A, Castiglione M, Ruepp B, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Giobbie-Hurder A, Maibach R, Sun Z, Regan M. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Res Treat 2020
Nov 7, 2020Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Nov 7, 2020Breast Cancer Res Treat 2020
Rabaglio Manuela, Thürlimann Beat, Colleoni Marco, Goldhirsch Aron, Gelber Richard D, Coates Alan S, Castiglione Monica, Ruepp Barbara, Wardley Andrew, Bonnefoi Hervé, Láng István, Neven Patrick, Harvey Vernon J, Ejlertsen Bent, Giobbie-Hurder Anita, Maibach Rudolf, Sun Zhuoxin, Regan Meredith M
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis P, Pavesi L, Ruhstaller T, Davidson N, Coleman R, Debled M, Buchholz S, Ingle J, Winer E, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates A, Gelber R, Goldhirsch A, Regan M, Climent M, Spazzapan S, Puglisi F, Pagani O, Fleming G, Walley B, Colleoni M, Láng I, Gomez H, Tondini C, Ciruelos E, Burstein H, Bonnefoi H, Bellet M, Martino S, Geyer C, Goetz M, Stearns V, Pinotti G, SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018; 379:122-137.
Jun 4, 2018Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Jun 4, 2018N Engl J Med 2018; 379:122-137
Francis Prudence A, Pavesi Lorenzo, Ruhstaller Thomas, Davidson Nancy E, Coleman Robert, Debled Marc, Buchholz Stefan, Ingle James N, Winer Eric P, Maibach Rudolf, Rabaglio-Poretti Manuela, Ruepp Barbara, Di Leo Angelo, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Regan Meredith M, Climent Miguel A, Spazzapan Simon, Puglisi Fabio, Pagani Olivia, Fleming Gini F, Walley Barbara A, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Ciruelos Eva, Burstein Harold J, Bonnefoi Hervé R, Bellet Meritxell, Martino Silvana, Geyer Charles E, Goetz Matthew P, Stearns Vered, Pinotti Graziella, SOFT and TEXT Investigators and the International Breast Cancer Study Group
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
Apr 10, 2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Apr 10, 2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
Jun 1, 2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Jun 1, 2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group